Welcome to our dedicated page for SPLASH BEVERAGE GROUP SEC filings (Ticker: SBEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Splash Beverage Group, Inc. filings document the regulatory record of a Nevada beverage operating company with common stock listed on NYSE American under SBEV. Its disclosures include Form 8-K material-event reports, periodic reporting notices, capital-structure items, shareholder voting matters, and governance updates.
The company's filings cover material agreements such as settlement amendments, board appointments and resignations, compensatory arrangements, equity-plan related grants, and amendments to its charter documents. Capital-structure disclosures include common stock registration details and the withdrawal of a Series A Preferred Stock designation. Reporting records also include annual-report timing disclosures and operating or financial-result categories tied to the company's beverage-brand portfolio.
Splash Beverage Group, Inc. reported a planned corporate rebranding to Endovia Health Sciences, Inc., effective August 24, 2026, including a new ticker symbol “EDVA” and launch of EndoviaSciences.com. The company describes this as the culmination of a six‑month strategic shift away from a legacy beverage focus toward a diversified cannabinoid health sciences platform.
The business strategy is organized around three pillars: commercial pharmaceutical assets, FDA‑regulated human and veterinary therapeutics, and consumer cannabinoid wellness and beverage products. Management emphasizes disciplined capital allocation, scientific development and strategic partnerships, while cautioning that execution depends on access to capital, maintaining key licenses, completing studies, obtaining regulatory approvals, protecting intellectual property and meeting debt obligations.
Splash Beverage Group, Inc., a Nevada corporation, reported a corporate name change. On August 5, 2026, the company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name. On August 6, 2026, it filed a Certificate of Correction to fix a scrivener’s error and confirm the new name as Endovia Health Sciences, Inc. The amended name became effective in Nevada upon filing. The company states that the name change will take effect on the NYSE American 10 days after it issues a press release announcing the change, subject to meeting NYSE American procedural requirements.
Splash Beverage Group, Inc. filed a resale registration covering up to 5,000,000 shares of common stock to be issued under an equity line of credit with C/M Capital Master Fund, LP. If fully drawn, shares outstanding would rise from 6,412,521 to 11,412,521, meaning substantial potential dilution. Splash is not selling shares in this offering and receives no proceeds from stockholder resales, but may receive up to $30,782,793 in gross proceeds from sales of stock to C/M under the purchase agreement.
The company has pivoted from beverages to the regulated cannabinoid and wellness markets, licensing exclusive worldwide rights to CannEpil® for human and veterinary uses and issuing preferred stock with $5,500,000 stated value as consideration. CannEpil® sales at the licensor have fallen sharply, and the product faces extensive clinical, regulatory and IP hurdles before meaningful U.S. commercialization.
Financially, Splash reported a $25.2 million net loss from continuing operations in 2025, a stockholders’ equity deficit of ($15,300,828), and an auditor going‑concern warning. The NYSE American has accepted a compliance plan through January 29, 2027, but the company continues to face significant risk of delisting despite a one‑for‑four reverse stock split effective July 24, 2026.
Splash Beverage Group, Inc. entered a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil as a potential FDA-regulated veterinary pharmaceutical for companion-animal oncology and chronic pain management. The program is structured to move CannEpil through the FDA Center for Veterinary Medicine, beginning with the Investigational New Animal Drug process toward potential Conditional Approval.
Lupvindol will lead scientific, product-development and regulatory activities, while Splash provides milestone-based funding, directs commercialization strategy and capital-markets efforts, and owns the resulting medical technology, study data, regulatory submissions and foreground intellectual property. Splash will decide on partnering or direct commercialization after key FDA submission milestones, and cautions there is no assurance of regulatory approval or revenue.
Splash Beverage Group, Inc. entered a Development and Collaboration Agreement with Lupvindol Biosciences Ltd. on July 31, 2026. Lupvindol will lead development and all FDA regulatory activities to advance a cannabinoid-based CannEpil veterinary product through the Center for Veterinary Medicine’s Investigational New Animal Drug process toward Conditional Approval.
The company will provide milestone funding of $95,000, $75,000, $65,000, $125,000, $250,000 and $500,000 tied to defined FDA and development steps, plus an ongoing 4% royalty on net sales until the 10th anniversary of first commercial sale. In lieu of the royalty, Lupvindol may elect to receive common shares valued at the greater of a five-day VWAP or the NYSE American minimum issue price. The agreement has an initial five-year term with automatic one-year renewals and includes detailed termination rights, including 90 days’ notice for convenience and a wind-down fee equal to 100% of the next unearned milestone.
Splash Beverage Group, Inc. entered into an addendum with Argent BioPharma Limited to its exclusive global CannEpil® license, expanding the field of use to include veterinary applications, revising royalties to 10% of Net Revenue from veterinary uses and 15% of Net Revenue from human uses, and extending certain contractual deadlines.
The company now holds exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases, initially focusing on companion-animal oncology and chronic pain. It plans to pursue FDA Center for Veterinary Medicine INAD and Conditional Approval pathways and is finalizing a joint venture to lead the veterinary program.
Splash Beverage Group, Inc. expanded its exclusive global CannEpil license with Argent BioPharma through an addendum that adds veterinary therapeutic applications to the existing human pharmaceutical program, sets royalties at 10% of Net Revenue for veterinary uses and 15% for human uses, and extends certain contractual deadlines.
The company plans to develop CannEpil, a pharmaceutical-grade CBD/THC oral formulation manufactured under EU-GMP standards, for companion-animal oncology and chronic pain, initially in dogs. It intends to pursue FDA Center for Veterinary Medicine Investigational New Animal Drug and Conditional Approval pathways and is finalizing a joint venture with an established cannabinoid pharmaceutical partner.
Splash Beverage Group, Inc. entered into amendments to settlement agreements with three prior investors, extending the schedule for remaining settlement payments. The company agreed that 50% of the remaining unpaid settlements, or $137,797.54, would be paid on July 15, 2026, which was paid that day.
The remaining 50%, also $137,797.54, is due on July 31, 2026, with interest accruing at 12% per annum plus reasonable attorney’s fees for the investors. These amendments revise February 2026 settlements related to amounts invested by the investors in October 2024.
Splash Beverage Group approved a structural change to its stock and disclosed a trading halt. The company filed a Certificate of Change in Nevada to implement a one-for-four reverse stock split of its issued and outstanding common shares, effective at 4:30 p.m. Eastern Time on July 24, 2026. Authorized common shares will be reduced proportionally from 400,000,000 to 100,000,000, and all options, warrants and restricted stock tied to the common will be adjusted accordingly. The common stock will receive a new CUSIP, 84862C401.
On July 16, 2026, NYSE American halted trading in the company’s stock because it was trading below $0.10 per share; the last trading price before the halt was $0.0936. The company expects trading to resume on a reverse stock split–adjusted basis when the market opens on July 27, 2026, while cautioning about the risk of potential delisting and the possibility that the halt may not be lifted as anticipated.
Splash Beverage Group, Inc. announced two major steps in its ongoing financial and listing-compliance strategy. The company has negotiated settlements with multiple legacy creditors covering approximately $3.3 million of accounts payable and accrued liabilities for aggregate cash consideration of approximately $550,000. Subject to final accounting review, Splash expects to recognize an approximate $2.75 million gain from the extinguishment of indebtedness, eliminating about 84% of the negotiated obligations while paying roughly 17% of their face value.
The Board of Directors also approved a 1-for-4 reverse stock split of issued and outstanding common stock, effective after the market closes on July 24, 2026, with post-split trading beginning July 27, 2026. The reverse split is intended to support continued compliance with NYSE American minimum share price requirements and is a key part of the exchange-approved compliance plan. Management highlights these actions, along with recent strategic investments and licensing deals, as elements of a broader transformation toward a cannabinoid health, wellness, and biopharmaceutical platform.